Molecular characterization of epithelial-mesenchymal transition and medical treatment related-genes in non-functioning pituitary neuroendocrine tumors

• DOI: 10.3389/fendo.2023.1129213
• Publication Date: 2023-03-22T12:46:37Z
• Authors: Joan Gil; Montserrat Marque...; Elena Valassi; Guillermo Serra; Isabel Salinas; Gemma Xifra; Paula Casano-Sancho; Cristina Carrato; Betina Biagetti; Gemma Sesmilo; Jennifer Marcos-Ruiz; Helena Rodriguez-...; Anna Rueda-Pujol; Anna Aulinas; Alberto Blanco; Cristina Hostalot; Andreu Simó-Servat; Fernando Muñoz; Marta Rico; Javier Ibáñez-Dom...; Esteban Cordero; Susan M. Webb; Mireia Jordà; Manel Puig-Domingo
• Keywords: Adenoma; Epithelial-Mesenchymal Transition; RC648-665; Epithelial-mesenchymal transition; Diseases of the endocrine glands. Clinical endocrinology; somatostatin analogs; 3. Good health; Somatostatin receptor ligands; Neuroendocrine Tumors; Endocrinology; ACTH-Secreting Pituitary Adenoma; Dopamine agonists; Somatostatin analogs; somatostatin receptor ligands; Non-functioning pituitary adenomas; dopamine agonists; Humans; Pituitary Neoplasms; non-functioning pituitary adenomas

Different medical therapies have been developed for pituitary adenomas. However, Non-Functioning Pituitary Neuroendocrine Tumors (NF-PitNET) shown little response to them. Furthermore, epithelial-mesenchymal transition (EMT) has linked resistance treatment in a significant number of tumors, including We aimed evaluate the expression EMT-related markers 72 NF-PitNET and 16 non-tumoral pituitaries. To further explore potential usefulness we assessed somatostatin receptors dopamine-associated genes. found that SNAI1, SNAI2, Vimentin, KLK10, PEBP1, Ki-67 SSTR2 were associated with invasive NF-PitNET. EMT phenomenon was more common than GH-secreting tumors. Interestingly, PEBP1 overexpressed recurrent NF-PitNET, could predict growth recurrence 100% sensitivity but only 43% specificity. In parallel previously reported studies, SSTR3 is highly expressed our cohort. heterogeneous among different histological variants very low levels silent corticotroph showed an enhanced phenomenon. targeting be good therapeutic candidate except adenomas, which express this receptor. addition, informative biomarker tumor regrowth, useful predictive medicine